Stock Scorecard

Stock Summary for BriaCell Therapeutics Corp - New (BCTX) - $0.58 as of 11/20/2024 7:48:54 PM EST

Total Score

8 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BCTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BCTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BCTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BCTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BCTX (16 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for BCTX

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer 9/8/2023 11:21:00 AM
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer 9/8/2023 11:00:00 AM
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders 8/31/2023 4:21:00 PM
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders - BriaCell Therapeutics ( NASDAQ:BCTXW ) , BriaCell Therapeutics ( NASDAQ:BCTX ) 8/31/2023 3:54:00 PM
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer 8/31/2023 12:51:00 PM
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer 8/31/2023 12:21:00 PM
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics ( SpinCo ) to Existing Shareholders - BriaCell Therapeutics ( NASDAQ:BCTXW ) , BriaCell Therapeutics ( NASDAQ:BCTX ) 8/25/2023 6:33:00 PM
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics ( SpinCo ) to Existing Shareholders 8/25/2023 6:33:00 PM
BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting - Investing News Network 8/18/2023 4:52:00 PM
BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer 8/16/2023 1:22:00 PM

Financial Details for BCTX

Company Overview
Ticker BCTX
Company Name BriaCell Therapeutics Corp - New
Country USA
Description BriaCell Therapeutics Corp. The company is headquartered in West Vancouver, Canada.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 7/31/2024
Next Earnings Date 12/12/2024

Stock Price History
Last Day Price 0.58
Price 4 Years Ago 4.17
Last Day Price Updated 11/20/2024 7:48:54 PM EST
Last Day Volume 400,683
Average Daily Volume 1,077,038
52-Week High 5.97
52-Week Low 0.46
Last Price to 52 Week Low 26.09%

Valuation Measures
Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -2.44
Free Cash Flow Ratio 29.00
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 0.49
Total Cash Per Share 0.02
Book Value Per Share Most Recent Quarter -0.13
Price to Book Ratio 17.03
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 36,183,200
Market Capitalization 20,986,256
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 76.40%
Reported EPS 12 Trailing Months -0.29
Reported EPS Past Year 0.00
Reported EPS Prior Year -1.17
Net Income Twelve Trailing Months -4,791,466
Net Income Past Year -4,791,466
Net Income Prior Year -20,302,394
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet
Total Cash Most Recent Quarter 862,089
Total Cash Past Year 862,089
Total Cash Prior Year 21,251,092
Net Cash Position Most Recent Quarter 835,125
Net Cash Position Past Year 836,103
Long Term Debt Past Year 25,986
Long Term Debt Prior Year 25,986
Total Debt Most Recent Quarter 26,964
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -13,415,967
Total Stockholder Equity Prior Year -3,777,181
Total Stockholder Equity Most Recent Quarter -13,415,967

Free Cash Flow
Free Cash Flow Twelve Trailing Months -24,575,773
Free Cash Flow Per Share Twelve Trailing Months -0.68
Free Cash Flow Past Year -24,582,929
Free Cash Flow Prior Year -23,744,863

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.06
MACD Signal -0.04
20-Day Bollinger Lower Band 0.49
20-Day Bollinger Middle Band 0.76
20-Day Bollinger Upper Band 1.02
Beta 1.82
RSI 37.44
50-Day SMA 2.11
150-Day SMA 5.05
200-Day SMA 5.28

System
Modified 11/20/2024 7:05:00 PM EST